Teicoplanin versus vancomycin for proven or suspected infection (Q24234764)

1

object named as

Alexandre B Cavalcanti

0 references

author name string

Anderson R Goncalves

2

0 references

Claudia S Almeida

3

0 references

Diogo DG Bugano

4

0 references

Eliezer Silva

Cochrane Database of Systematic Reviews

5

0 references

publication date

16 June 2010

0 references

published in

0 references

cites work

Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): review of 10 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Glycopeptide resistance in Staphylococcus haemolyticus during treatment with teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Once daily antibiotic regimen in paediatric oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Activity of teicoplanin against coagulase-negative staphylococci isolated from patients undergoing continuous peritoneal dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Glycopeptide resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Treatment of Clostridium difficile-associated disease with teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Protein binding and serum bactericidal activities of vancomycin and teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Soft tissue infections in oral, maxillofacial, and plastic surgery. Bacterial spectra and antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Safety and efficacy of glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Dalbavancin: an investigational glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Pharmacokinetics and dosage adjustment of antibiotics during continuous extracorporeal lung assistance and hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Glycopeptide tolerance in Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Comparison of vancomycin and teicoplanin for prophylaxis of sepsis with coagulase negative staphylococci (CONS) in very low birth weight (VLBW) infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Stability of the MICs of various antibiotics in different clonal populations of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Activity of various glycopeptides against an inducibly vancomycin-resistant strain of Enterococcus faecium (D366).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Emergence of vancomycin-intermediate Staphylococcus aureus and S. sciuri, Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Anaerobic vaginosis: therapeutic and epidemiological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

The comparative efficacy and safety of teicoplanin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Comparative safety of teicoplanin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Subcellular localization of tobramycin and vancomycin given alone and in combination in proximal tubular cells, determined by immunogold labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

21 January 2018

Vancomycin: an update

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Developing a consensus classification system for acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Do Vancomycin Serum Levels Predict Failures of Vancomycin Therapy or Nephrotoxicity in Cancer Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Explaining heterogeneity in meta-analysis: a comparison of methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

Teicoplanin versus vancomycin for proven or suspected infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

A general parametric approach to the meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Methicillin-resistant Staphylococcus aureus in Europe

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Glycopeptide sensitivity of staphylococci

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

The effect of teicoplanin on leukocytic activity and intraleukocytic micro-organisms

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

A critical review of the dosage of teicoplanin in Europe and the USA.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Success of teicoplanin over vancomycin in streptococcal endocarditis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Acquisition of methicillin-resistant Staphylococcus aureus in the acute care setting: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Antibacterial activity of teichomycin, a new glycopeptide antibiotic, in comparison to vancomycin

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

1 reference

7 January 2021

Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with and without amikacin given intravenously

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

The potential impact on clinical practice of differences in the in-vitro activity of vancomycin and teicoplanin

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Gram-positive infections in neutropenic patients: glycopeptide antibiotic choice

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Antistaphylococcal activity of vancomycin and teicoplanin under anaerobic conditions

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Bolus or infusion teicoplanin for intravascular catheter associated infections in immunocompromised patients?

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

The comparative efficacy and safety of teicoplanin and vancomycin

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Community-acquired methicillin-resistant Staphylococcus aureus: an ever-emerging epidemic

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Zeckel ML. A closer look at vancomycin, teicoplanin and antimicrobial resistance. J Chemother 1997; 9: 311-335

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021

Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007022.PUB2

7 January 2021